FOUNDATION LYGATURE
- Web page: http://www.lygature.org
- Country: Netherlands
- project . 2018 - 2022Funder: EC Project Code: 779316Overall Budget: 5,357,030 EURFunder Contribution: 5,357,030 EUROpen Access mandate for Publications and Research DataPartners: Clinica Universidad de Navarra, Stichting Sanquin Bloedvoorziening, ICS, ICOMETRIX NV, FOUNDATION LYGATURE, WWU, University of Antwerp, UZA
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available. It is the leading cause of non-traumatic disabling neurological disease in young adults with more than 500,000 people affected in...
- project . 2019 - 2022Funder: EC Project Code: 820880Overall Budget: 2,131,610 EURFunder Contribution: 999,698 EUROpen Access mandate for Publications and Research DataPartners: NORGES PARKINSONFORBUND, KCL, Ud'A, ASTRAZENECA AB, FOUNDATION LYGATURE, MU, STAVANGER UNIVERSITETSSJUKEHUS, TUD, University of Exeter, PARKINSON'S UK
Parkinson Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is an unmet clinical need to treat Parkinson disease with mild cognitive impairment (PD-MCI). There is ample evidence from epidemiological studies as well as (pre...
- project . 2019 - 2025Funder: EC Project Code: 853979Overall Budget: 31,416,000 EURFunder Contribution: 12,300,000 EUROpen Access mandate for PublicationsPartners: INSERM, University of Liverpool, NOSOPHARM, Medical University of Vienna, BIOASTER FONDATION DE COOPERATION SCIENTIFIQUE, ERASMUS MC, Fraunhofer, NBT, FOUNDATION LYGATURE, EVOTEC INTERNATIONAL GMBH...
AntiMicrobial Resistance (AMR) is a global and serious threat to human health. Gram-negative bacteria are widely regarded as the culprit representing one of the gravest dangers. Indeed, there is a dearth of new agents able to address AMR in Gram-negative bacteria, espec...
- project . 2014 - 2018Funder: EC Project Code: 602666Open Access mandate for Publications Special Clause 39Partners: STICHTING VU, Fraunhofer, CSIC, EUROPEAN SCREENINGPORT GMBH, TBRI, University of Kent, University of Antwerp, FOUNDATION LYGATURE, IOTA PHARMACEUTICALS LTD, FIOCRUZ...
- project . 2019 - 2022Funder: EC Project Code: 806999Overall Budget: 7,644,400 EURFunder Contribution: 4,999,760 EUROpen Access mandate for PublicationsPartners: STICHTING VUMC, UOXF, SOFTWARE AG, Karolinska Institutet Innovations (Sweden), Eli Lilly and Company Limited, ALTOIDA SA ALTOIDA LTD, AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN, Fraunhofer, Novartis Pharma AG, KCL...
There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful c...
Powered by OpenAIRE Research Graph